Accessibility Menu
Gelteq logo

Gelteq(NASDAQ) GELS

Market Cap$6.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-81%
5 YearN/A
1 Year-57%
1 Month-6%
$0.57
+2.63%
+0.01Today
Gelteq last closing stock price
MetricPriceDate
Last closeUSD 0.562026-08-19
Gelteq stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.58%USD 0.572026-08-12
1 month-5.75%USD 0.592026-07-20
3 month+27.5%USD 0.442026-05-21
Year to date-30.51%USD 0.802025-12-31
1 year-56.57%USD 1.282025-08-19
Since inception-81.09%USD 2.942024-10-29

Gelteq Financials at a Glance

Market Cap

$6.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$178.59K

Net Income (TTM)

-A$5.60M

EPS (TTM)

-$0.45

P/E Ratio

-1.25

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$0.57

Volume

11,140.517

Open

$0.56

Previous Close

$0.56

Daily Range

$0.53 - $0.57

52-Week Range

$0.39 - $2.02

Estimated Earnings Date

N/A

GELS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gelteq

Gelteq Limited is an innovative company based in Caulfield, Australia, specializing in advanced gel-based delivery methods for human and animal applications. Established in 2017, Gelteq offers customizable gel formulations for pharmaceuticals, nutritional supplements, and veterinary care.

Products and Services
  • Customizable gel formulations for pharmaceuticals
  • Nutritional supplements, including sports-related products
  • Veterinary care items with advanced delivery methods
Growth Outlook
  • Market demand for gel-based delivery systems is increasing
  • Expansion into new markets anticipated in the coming years
  • Focus on research and development to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 89,296 AUD, indicating stable performance
  • Trailing twelve months (TTM) gross profit margin stands at 1
  • Current ratio of 0.09 suggests liquidity challenges
Gelteq Limited operates in the Drug Manufacturers - Specialty & Generic industry, focusing on innovative delivery methods that cater to a diverse range of applications. The company’s customizable gel formulations are designed to meet the specific needs of various sectors, including pharmaceuticals and veterinary care. The growth outlook for Gelteq is promising, driven by increasing market demand for gel-based delivery systems. The company is poised to expand into new markets, leveraging its research and development capabilities to enhance its product offerings. Financially, Gelteq reported a recent quarterly revenue of 89,296 AUD, reflecting stable performance amidst ongoing operational challenges. The trailing twelve months (TTM) gross profit margin of 1 indicates potential for profitability as the company scales its operations. However, a current ratio of 0.09 highlights liquidity challenges that may need to be addressed for sustainable growth. Overall, Gelteq Limited presents an intriguing opportunity for investors interested in innovative healthcare solutions, particularly in the specialty and generic drug manufacturing sector.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

18

CEO

Nathan J. Givoni

Website

www.gelteq.com

Headquarters

Clayton, VIC 3800, AU

GELS Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1986.04%

Net Income Margin

-2095.34%

Return on Equity

-24.94%

Return on Capital

-27.45%

Return on Assets

-18.59%

Earnings Yield

-80.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.18M

Volume

11.14K

Avg. Volume

3.62M

Financials (TTM)

Gross Profit

A$178.59K

Operating Income

-A$14.61M

EBITDA

-A$3.88M

Operating Cash Flow

-A$641.30K

Capital Expenditure

-A$83.94K

Free Cash Flow

-A$1.83M

Cash & ST Invst.

A$9.35K

Total Debt

A$5.11M

Gelteq Performance Analysis

Gelteq annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 107,006N/A
20232023-06-30AUD 53,711-49.8%
20242024-06-30AUD 0N/A
20252025-06-30AUD 107,277N/A
Gelteq sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31N/A
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Gelteq annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.26N/A
20232023-06-30AUD -0.25-3.5%
20242024-06-30AUD -0.25-1.5%
20252025-06-30AUD -0.4374.3%
Gelteq sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31N/A
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$89.30K

+8929700.0%

Gross Profit

A$89.30K

+8929700.0%

Gross Margin

100.00%

N/A

Market Cap

$6.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$345.39K

N/A

Employees

18

N/A

Net Income

-A$1.87M

-97.4%

EBITDA

-A$1.46M

-177.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$9.35K

-93.6%

Total Debt

A$5.11M

+48.6%

Accounts Receivable

A$414.78K

+197.5%

Inventory

A$0.00

-100.0%

Long Term Debt

A$13.55K

-99.1%

Short Term Debt

A$5.10M

+157.2%

Return on Assets

-18.59%

N/A

Return on Invested Capital

-24.88%

N/A

Free Cash Flow

-A$367.21K

-203.7%

Operating Cash Flow

-A$302.15K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMNNImunon, Inc.
$1.54-1.76%
IMRNImmuron Limited
$1.17-1.68%
EVGNEvogene Ltd.
$0.56-6.39%
BGLCBioNexus Gene Lab Corp.
$1.58+0.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.77+0.06%
IBITiShares Bitcoin Trust
$40.96+0.06%
SPCXSpace Exploration Technologies
$130.98-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.89-0.03%

Questions About GELS

What is the current price of Gelteq?

Gelteq is trading at $0.55 per share.

What is the 52-week range for Gelteq?

Over the past 52 weeks, Gelteq has traded between $0.39 and $2.02.

How much debt does Gelteq have?

As of the most recent reporting period, Gelteq reported total debt of A$2.76M.

How much cash does Gelteq have on hand?

Gelteq reported A$225.87K in cash and cash equivalents in its most recent financial results.

What is Gelteq’s dividend yield?

Gelteq does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services